RecruitingPhase 1NCT07067385

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Exploratory Clinical Study of Neoantigen Tumor Vaccine Therapy for Gastrointestinal Solid Tumors

Sponsor

Ruijin Hospital

Enrollment

40 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Gastrointestinal Tumors Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy

Summary

Evaluating the efficacy and safety of Neoantigen Personalized Cancer Vaccine deepGeneAI-001 in combination with Sintilimab in the treatment of Gastrointestinal Solid Tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Neoantigen Personalized Cancer Vaccine for people with gastrointestinal tumors and personalized neoantigen vaccine in combination with anti-pd-1 inhibitors in standard therapy-failed and adjuvant therapy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALNeoantigen Personalized Cancer Vaccine

Cohort 1: subjects will receive neoantigen tumor vaccine combination with Sintilimab. Cohort 2: subjects will receive neoantigen tumor vaccine combination with Sintilimab and chemotherapy .

Locations(1)

Ruijin Hospital

Shanghai, SH, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07067385

Related Trials

A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model: A Multi-center Prospective Randomized Controlled Trial

NCT077121076 locations

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT0740663316 locations

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT072794281 location

A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT072324071 location

Combined Screening for Gastrointestinal Tumors

NCT064780302 locations